The relationship between ADHD, MPH use, and growth appears complex, given that a consistent effect could not be observed across all ADHD conditions.
Quillivant XR, a central nervous system stimulant, is indicated to treat ADHD in patients aged 6 years and older.
The authors identified 4 anatomical patterns in participants with attention-deficit/hyperactivity disorder associated with head size, delayed development, symptoms of attention-deficit/hyperactivity disorder, and cognitive performance.
Patients with ADHD may require careful monitoring to permit early detection and treatment of disorders of the basal ganglia or cerebellum.
These results do not support existing hypotheses on the role of anxiety as either an exacerbating or protective factor for ADHD-related aggression.
Researchers analyzed neuroimaging data from a group of 1093 adolescents from the IMAGEN project.
This research rejects any association between increased risk for ADHD and changes in children's microbiota related to cesarean delivery or antibiotic use.
Improving Medication Adherence in ADHD Lowers Risk for Oppositional Defiant Disorder, Conduct Disorder in AdulthoodSeptember 21, 2018
Researchers found that children who were compliant with drug therapy had a significantly lower risk for oppositional defiant disorder or conduct disorder than those who were noncompliant.
Clinicians may find these data useful in considering the mediating effects of family function and psychiatric comorbidities among patients with ADHD.
This increase may be the result of expanded continuing medical education regarding ADHD that has raised physician awareness, as well as modifications in diagnostic criteria.
Guidelines on which ADHD medications should be preferred across different age groups are unclear, and the safety and benefits of these medications remain controversial.
The authors argue that, given the findings of this study, the awareness of the detrimental effects of both smoking and depression upon children should be raised among parents.
From 1997-1998 to 2015-2016, there was an increase in the prevalence of ADHD among children.
The FDA stated that the dasotraline NDA cannot be approved in its current form and is requiring additional data to further assess the efficacy and tolerability of the drug.
Compared with controls, those with subthreshold ADHD experienced greater impairments in social functioning and had higher rates of requiring extra help in school.
Methylphenidate should be considered as a first choice for the treatment of ADHD in children and adolescents.
In this prospective cohort trial, teens with significant ADHD symptoms were slightly more likely to be associated with a higher frequency of digital media use.
The 7 treatments included in the study were amphetamines (including lisdexamfetamine), atomoxetine, bupropion, clonidine, guanfacine, methylphenidate, and modafinil.
Jornay PM utilizes the proprietary Delexis drug delivery platform which consists of 2 functional film coatings: the first layer delays the initial drug release for up to 10 hours and the second layer helps control the release rate of the active ingredient throughout the day.
These results indicate an association between adolescent engagement in digital media activities and subsequent ADHD symptoms.
There is a modest, but statistically significant, association between higher frequency of digital media use and subsequent symptoms of ADHD among adolescents.
These findings illustrate potential gains of reducing the number of preterm births and the importance of providing custom support to children born preterm to prevent neurodevelopmental problems.
Nonstimulants may be an appropriate alternative in cases in which co-occurring conditions might prevent the administration of stimulants.
Food insecurity may be linked to behavioral problems and poorer cognitive performance in children.
The high risk for several neuropsychiatric and developmental disorders supports more extended use of genetic testing in child and adolescent psychiatry.
Early preterm birth is associated with a higher level of ADHD symptoms in preschool children.
Investigators conducted a retrospective observational study to assess the impact of psychostimulant medication on BMI and height in a group of children and adolescents with ADHD.
Medication continuity in youth with ADHD is affected by several potentially modifiable factors that could be productive targets of intervention for pediatricians.
Exposure to hypertensive disorders of pregnancy may be associated with an increase in the risk for ASD and ADHD in offspring.
These findings offer preliminary evidence of the validity of the short UPPS-P-C to screen for impulsivity traits in both typically developing children and in those with ADHD.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Cardioprotective Treatment May Reduce Adverse Effects in Schizophrenia
- The Challenges of Identifying Biomarkers of Psychiatric Illness
- FDA Approves Powerful New Opioid Despite Criticisms
- Impulsivity in Bipolar Disorder, Borderline Personality Disorder, ADHD
- Oral Therapy for Suicidal Bipolar Depression Gets Breakthrough Designation
- Cannabis Use in Adolescence Associated With Poorer Mental Health Outcomes
- Updates in Borderline Personality Disorder: Your Questions Answered
- Violent Video Games Tied to Physical Aggression
- Shame Drives Suicidal Ideation Among Veterans With PTSD
- Long-term Healthy Diet Associated With Greater Hippocampal Volumes
- FDA to Ban Most Flavored Electronic Cigarettes
- Predictors of CBT Outcomes Identified in Youths With Anxiety Disorders
- Happy Childhood Memories Associated With Better Health
- FDA Launches MyStudies Mobile App in Effort to Increase Access to Real World Patient Data
- Heart Rate Variability Predicts Treatment Response in Anxious Depression